150 related articles for article (PubMed ID: 37368917)
1. PAK1 copy number in breast cancer-Associations with proliferation and molecular subtypes.
Skjervold AH; Valla M; Ytterhus B; Bofin AM
PLoS One; 2023; 18(6):e0287608. PubMed ID: 37368917
[TBL] [Abstract][Full Text] [Related]
2. CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis.
Valla M; Klæstad E; Ytterhus B; Bofin AM
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):67-77. PubMed ID: 35459982
[TBL] [Abstract][Full Text] [Related]
3. DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis.
Valla M; Opdahl S; Ytterhus B; Bofin AM
Breast Cancer Res Treat; 2021 May; 187(1):57-67. PubMed ID: 33616774
[TBL] [Abstract][Full Text] [Related]
4. MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
Klæstad E; Opdahl S; Engstrøm MJ; Ytterhus B; Wik E; Bofin AM; Valla M
Breast Cancer Res Treat; 2020 Feb; 180(1):73-86. PubMed ID: 31950385
[TBL] [Abstract][Full Text] [Related]
5. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
Schraml P; Schwerdtfeger G; Burkhalter F; Raggi A; Schmidt D; Ruffalo T; King W; Wilber K; Mihatsch MJ; Moch H
Am J Pathol; 2003 Sep; 163(3):985-92. PubMed ID: 12937139
[TBL] [Abstract][Full Text] [Related]
6. ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.
Klæstad E; Sawicka JE; Engstrøm MJ; Ytterhus B; Valla M; Bofin AM
Breast Cancer Res Treat; 2021 Feb; 186(1):65-77. PubMed ID: 33389351
[TBL] [Abstract][Full Text] [Related]
7.
Bofin AM; Ytterhus B; Klæstad E; Valla M
J Clin Pathol; 2022 Jul; 75(7):459-464. PubMed ID: 33753561
[TBL] [Abstract][Full Text] [Related]
8. FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
Valla M; Engstrøm MJ; Ytterhus B; Hansen ÅK; Akslen LA; Vatten LJ; Opdahl S; Bofin AM
Breast Cancer Res Treat; 2017 Apr; 162(2):243-253. PubMed ID: 28124285
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A
Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and cellular signature of PAK1 in human bladder cancer.
Huang K; Chen G; Luo J; Zhang Y; Xu G
Tumour Biol; 2015 Apr; 36(4):2359-68. PubMed ID: 25412958
[TBL] [Abstract][Full Text] [Related]
11. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
[TBL] [Abstract][Full Text] [Related]
13. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
Lundgren K; Holm K; Nordenskjöld B; Borg A; Landberg G
Breast Cancer Res; 2008; 10(5):R81. PubMed ID: 18823530
[TBL] [Abstract][Full Text] [Related]
14. Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum.
Qui S; Takeshita T; Sueta A; Tomiguchi M; Goto-Yamaguchi L; Hidaka K; Suzu I; Yamamoto Y; Iwase H
Breast Cancer; 2021 May; 28(3):746-754. PubMed ID: 33538993
[TBL] [Abstract][Full Text] [Related]
15. S100A8 gene copy number and protein expression in breast cancer: associations with proliferation, histopathological grade and molecular subtypes.
Børkja MLB; Giambelluca MS; Ytterhus B; Prestvik WS; Bjørkøy G; Bofin AM
Breast Cancer Res Treat; 2023 Sep; 201(2):339-350. PubMed ID: 37450087
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatics exploration of PAK1 (P21-activated kinase-1) revealed potential network gene elements in breast invasive carcinoma.
Yellapu NK; Pulaganti M; Pakala SB
J Biomol Struct Dyn; 2017 Aug; 35(10):2269-2279. PubMed ID: 27456030
[TBL] [Abstract][Full Text] [Related]
17. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
[TBL] [Abstract][Full Text] [Related]
18. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
Falck AK; Fernö M; Bendahl PO; Rydén L
BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
[TBL] [Abstract][Full Text] [Related]
19. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.
Prudnikova TY; Villamar-Cruz O; Rawat SJ; Cai KQ; Chernoff J
Oncogene; 2016 Apr; 35(17):2178-85. PubMed ID: 26257058
[TBL] [Abstract][Full Text] [Related]
20. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
Natrajan R; Weigelt B; Mackay A; Geyer FC; Grigoriadis A; Tan DS; Jones C; Lord CJ; Vatcheva R; Rodriguez-Pinilla SM; Palacios J; Ashworth A; Reis-Filho JS
Breast Cancer Res Treat; 2010 Jun; 121(3):575-89. PubMed ID: 19688261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
